Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 14;4(6):FSO307.
doi: 10.4155/fsoa-2018-0019. eCollection 2018 Jul.

Invasive fungal infections in high-risk patients: report from TIMM-8 2017

Livio Pagano  1   1 , Susan Mayor  2   2
Affiliations

Invasive fungal infections in high-risk patients: report from TIMM-8 2017

Livio Pagano et al. Future Sci OA. .

Abstract

Trends in Medical Mycology (TIMM) is the biennial meeting of the Infectious Disease Group of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Confederation of Medical Mycology (ECMM). It brings together clinicians and researchers from across the world to share the latest R&Ds in medical mycology. Despite advances in treatment, invasive fungal infections remain a major cause of morbidity and mortality in certain high-risk groups of patients, particularly in immunocompromised patients, including those undergoing solid organ transplantation and those with acute leukemia. The challenges for clinicians are now compounded by the rapid development of multidrug resistance. The latest data and approaches to identifying patients at high risk for invasive fungal infections, ensuring early diagnosis and achieving effective treatment, including when and how to use therapeutic drug monitoring with azoles, were shared with >1000 clinicians and researchers from around the world attending the eighth TIMM, held in Belgrade, Serbia, in October 2017 (TIMM-8 2017).

Keywords: antifungal resistance; azole drug monitoring; invasive fungal infections; prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure L Pagano participated as a speaker at the MSD symposium held at TIMM-8. He is an advisory board member and speaker for Gilead, Cidara, MSD, and Pfizer. S Mayor's attendance at TIMM-8 and her contribution to the writing of the report were supported by MSD. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing assistance was utilized in the production of this manuscript, and the funding source was MSD.

References

    1. Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97:459–463. - PMC - PubMed
    1. Neofytos D, Lu K, Hatfield-Seung A, et al. Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagn. Microbiol. Infect. Dis. 2013;75:144–149. - PMC - PubMed
    1. Tang JL, Kung HC, Lei WC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS ONE. 2015;10:e0128410. - PMC - PubMed
    1. Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin. Infect. Dis. 2012;55:1515–1521. - PubMed
    1. Nucci M, Garnica M, Gloria AB, et al. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin. Microbiol. Infect. 2013;19:745–751. - PubMed

LinkOut - more resources